Awards Nomination 20+ Million Readerbase
Indexed In
  • Open J Gate
  • Genamics JournalSeek
  • Academic Keys
  • JournalTOCs
  • ResearchBible
  • Electronic Journals Library
  • RefSeek
  • Hamdard University
  • OCLC- WorldCat
  • Proquest Summons
  • SWB online catalog
  • Virtual Library of Biology (vifabio)
  • Publons
  • MIAR
  • Euro Pub
  • Google Scholar
Share This Page
Recommended Webinars & Conferences
Journal Flyer
Flyer image

Evgeny Krynetskiy

Evgeny Krynetskiy

Evgeny Krynetskiy
Associate Professor, School of Pharmacy
Temple University, USA


Evgeny Krynetskiy is an Associate Professor in the Pharmaceutical Sciences, Department of School of Pharmacy, Temple University, Philadelphia, USA. He earned his PhD at Moscow State University, Moscow, Russia. Currently he is the Director of Jayne Haines Center for Pharmacogenomics and Drug Safety at Temple University, School of Pharmacy and holds a secondary appointment as an Associate Professor in the Fels Institute for Cancer Research and Molecular Biology, Temple University. He has published over 80 reviewed papers and was an author of two book chapters. For more than 10 years he has been teaching Pharmacogenomics to professional and graduate students at Schools of Pharmacy. He served as a reviewer of peer reviewed journals in the area of pharmacogenetics and genomics. He is a recipient of Karnofsky Fellowship for Cancer Research at St. Jude Childrenmiddot s Research Hospital.

Research Interest

Dr. Krynetskiy s lab concentrates on the study of DNA damage sensors and their role in initiating apoptosis after chemotherapy. This research includes development of model experimental systems based on murine embryonic fibroblasts and different types of human cancer cell lines, generation and computational processing of gene expression and proteomic data following drug treatment. The second area of Dr. Krynetskiy s interests focuses on the role of inherited factors that modulate drug response and cause adverse drug reactions, such as genetic polymorphism of drug-metabolizing enzymes and drug targets. The ultimate goal of this study is to predict and prevent adverse reactions to drugs in genetically predisposed patients.